AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain (WR; > or =5 lb gain)
Number of subjects: 248
Study 18719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued weight loss
Number of subjects: 248
Study 18719654 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 248
Study 15853835 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + 17beta-oestradiol
Number of subjects: 8
Study 15853835 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + placebo
Number of subjects: 8
Study 15853835 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 8
Study 15853835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 8
Study 16285496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 31
Study 10858176 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE (Self‐Study Acceleration with Graphic Evidence), a Web‐based tutorial system
Number of subjects: 162
Study 10858176 — intervention group
Group type: COMPARATOR
Intervention: Printed materials (control group)
Number of subjects: 162
Study 8890677 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms assessment
Number of subjects: 181
Study 1815112 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural block (IPB) with 10 ml 0.5% plain bupivacaine (n = 15)
Number of subjects: 25
Study 1815112 — intervention group
Group type: COMPARATOR
Intervention: Spinal analgesia with 15 mg 0.5% heavy bupivacaine and meperidine 1 mg/kg IV and diazepam 10 mg total dose (n = 10)
Number of subjects: 25
Study 6367554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 52
Study 6367554 — intervention group
Group type: COMPARATOR
Intervention: D5W (control)
Number of subjects: 52
Study 30651059 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call and text message intervention provided by trained nurses
Number of subjects: 120
Study 30651059 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 120
Study 30521530 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive health facility‐ and community‐based program delivered through the HIV/AIDS program platform
Number of subjects: 1250
Study 30521530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1250
Study 30521530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention facilities
Number of subjects: 1250
Study 30521530 — intervention group
Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 1250
Study 27621395 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 108
Study 27621395 — intervention group
Group type: COMPARATOR
Intervention: FU/LV (infusional fluorouracil/leucovorin)
Number of subjects: 108
Study 27621395 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 108
Study 27621395 — intervention group
Group type: COMPARATOR
Intervention: FU/LV
Number of subjects: 108
Study 25376160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release trazodone (150-450 mg)
Number of subjects: 363
Study 25376160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 22289412 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with complex milk lipid (11 to 12 μg/ml gangliosides)
Number of subjects: 29
Study 22289412 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with complex milk lipid
Number of subjects: 29
Study 22289412 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (control group)
Number of subjects: 29
Study 22289412 — intervention group
Group type: COMPARATOR
Intervention: Reference group (exclusively breast-fed infants)
Number of subjects: 29
Study 19889508 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based diabetes self-management support (DSMS) intervention
Number of subjects: 77
Study 19889508 — intervention group
Group type: COMPARATOR
Intervention: Control period (weekly educational newsletters)
Number of subjects: 77
Study 18303079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEEs) 0.625 mg/d for 12 weeks
Number of subjects: 27
Study 18303079 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (E2) 0.05 mg/d for 12 weeks
Number of subjects: 27
Study 16002420 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin/tazobactam (13.5 g over 24 h)
Number of subjects: 262
Study 16002420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of piperacillin/tazobactam (3.375 g every 6 h)
Number of subjects: 262
Study 16002420 — intervention group
Group type: COMPARATOR
Intervention: Both infusion methods (intermittent and continuous)
Number of subjects: 262
Study 12466370 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) infusion
Number of subjects: 12
Study 12466370 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 10364643 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE epsilon4 carriers
Number of subjects: 81
Study 10364643 — intervention group
Group type: COMPARATOR
Intervention: ApoE epsilon4 noncarriers
Number of subjects: 81
Study 10364643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) subjects
Number of subjects: 81
Study 10364643 — intervention group
Group type: COMPARATOR
Intervention: Subjects at risk for AD (OCI and SCI)
Number of subjects: 81
Study 10364643 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ApoE epsilon4 allele
Number of subjects: 81
Study 8770708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive plasma exchange (IPE) or whole blood exchange (WBE) in addition to standard medical therapy
Number of subjects: 8
Study 8770708 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 8
Study 2061418 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive program based on plaque control and topical application of fluoride, with scaling, root planning, and conventional caries therapy; preventive measures recalled every 2-3 months for 6 years, then 1-2 times per year for 9 years, with a subgroup recalled 3-6 times per year.
Number of subjects: 375
Study 6349652 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (300 mg per day for 4 weeks)
Number of subjects: 41
Study 6349652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31941416 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone (SMA)
Number of subjects: 25
Study 31941416 — intervention group
Group type: EXPERIMENTAL
Intervention: video game (VID)
Number of subjects: 25
Study 31941416 — intervention group
Group type: COMPARATOR
Intervention: control (CON)
Number of subjects: 25
Study 30520944 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 4415
Study 30520944 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMISE-PTP
Number of subjects: 4415
Study 28403154 — intervention group
Group type: EXPERIMENTAL
Intervention: 56mg/day magnesium cream
Number of subjects: 25
Study 28403154 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study 26284652 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine (3 + 1 and 2 + 1 schedules)
Number of subjects: 30527
Study 26284652 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine (catch-up schedules)
Number of subjects: 30527
Study 26284652 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B or A vaccine (control)
Number of subjects: 30527
Study 23990567 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (initiated immediately)
Number of subjects: 957
Study 23990567 — intervention group
Group type: COMPARATOR
Intervention: Standard ART (according to ongoing WHO criteria)
Number of subjects: 957
Study 23990567 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 957
Study 21136163 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi/ARB
Number of subjects: 535
Study 21136163 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive medications
Number of subjects: 535
Study 21136163 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive medications
Number of subjects: 535
Study 19070525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (15 mg/kg/day, twice a day for three days)
Number of subjects: 75
Study 19070525 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (1 g, twice a day for five days)
Number of subjects: 75
Study 19070525 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (control)
Number of subjects: 75
Study 19070525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 75
Study 19070525 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 75
Study 17579171 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-slice CT planimetry of the aortic valve area
Number of subjects: 36
Study 15559872 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for ECG analysis
Number of subjects: 22
Study 15559872 — intervention group
Group type: COMPARATOR
Intervention: Standard ECG analysis without algorithm
Number of subjects: 22
Study 11385811 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer (breath-actuated multidose dry powder inhaler)
Number of subjects: 0
Study 11385811 — intervention group
Group type: COMPARATOR
Intervention: Established inhalational devices (pressurized metered dose inhalers)
Number of subjects: 0
Study 11385811 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 0
Study 9879160 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tool for addictive disease
Number of subjects: 52
Study 7978134 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg-1
Number of subjects: 54
Study 7978134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2534744 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 14
Study 2534744 — intervention group
Group type: COMPARATOR
Intervention: Reference subjects
Number of subjects: 14
Study 7952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 27
Study 31812949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) test on the hand before Cold Pressor Test (CPT)
Number of subjects: 60
Study 31812949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) test on the hand during Cold Pressor Test (CPT)
Number of subjects: 60
Study 31812949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT) test on the hand
Number of subjects: 60
Study 31812949 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) test on the hand
Number of subjects: 60
Study 31812949 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) test on the face
Number of subjects: 60
Study 31812949 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) test on the foot
Number of subjects: 60
Study 31048584 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fetal repair of myelomeningocele with extended BMI criteria (BMI 35-40)
Number of subjects: 11
Study 28569553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 91
Study 28569553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training + electrical myostimulation
Number of subjects: 91
Study 28569553 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise training)
Number of subjects: 91
Study 28569553 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (exercise training + electrical myostimulation)
Number of subjects: 91
Study 25693013 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of propranolol per kilogram per day for 6 months
Number of subjects: 460
Study 25693013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 25693013 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (successful treatment)
Number of subjects: 460
Study 25693013 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and Placebo
Number of subjects: 460
Study 22118955 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg/d for 8 weeks
Number of subjects: 49
Study 21281257 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour training program on the VR unit
Number of subjects: 14
Study 19758254 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic antimicrobial therapy (PACT) with 47 J cm(‐2) of irradiation
Number of subjects: 20
Study 19758254 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic antimicrobial therapy (PACT) with 94 J cm(‐2) of irradiation
Number of subjects: 20
Study 19758254 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with 94 J cm(‐2) of irradiation alone
Number of subjects: 20
Study 17302913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulverized candesartan cilexetil
Number of subjects: 21
Study 17302913 — intervention group
Group type: COMPARATOR
Intervention: Pulverized irbesartan
Number of subjects: 21
Study 17302913 — intervention group
Group type: COMPARATOR
Intervention: Pulverized losartan
Number of subjects: 21
Study 17302913 — intervention group
Group type: COMPARATOR
Intervention: Pulverized telmisartan
Number of subjects: 21
Study 17302913 — intervention group
Group type: COMPARATOR
Intervention: Pulverized valsartan
Number of subjects: 21
Study 15339411 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhifang I Decoction
Number of subjects: 46
Study 15339411 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang Capsule
Number of subjects: 46
Study 11435905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine and L-phenylalanine
Number of subjects: 15
Study 11435905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9555778 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal-guided strategy (TEE) with brief anticoagulation
Number of subjects: 3000
Study 9555778 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation strategy
Number of subjects: 3000
Study 9555778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 3000
Study 7844206 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist (GnRH-a) in a long-term protocol with human menopausal gonadotrophin (HMG)
Number of subjects: 57
Study 7844206 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin-releasing hormone agonist (GnRH-a) in a short protocol with human menopausal gonadotrophin (HMG)
Number of subjects: 57
Study 3132484 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000‐mg calcium diet for 8 weeks
Number of subjects: 9
Study 3132484 — intervention group
Group type: EXPERIMENTAL
Intervention: 300‐mg calcium diet for 1, 2, 4, and 8 weeks
Number of subjects: 9
Study 29808014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study 27607517 — intervention group
Group type: EXPERIMENTAL
Intervention: NESAP (3.5 mA, 10 Hz)
Number of subjects: 162
Study 27607517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 162
Study 27607517 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 162
Study 27607517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose plus NESAP
Number of subjects: 162
Study 24084586 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet plus a behavioral weight management intervention (DASH-WM)
Number of subjects: 144
Study 24084586 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet alone (DASH-A)
Number of subjects: 144
Study 24084586 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 144
Study 22388304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus diltiazem (200 μg nitroglycerin plus 2.5 mg diltiazem)
Number of subjects: 150
Study 22388304 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin alone (200 μg nitroglycerin plus placebo)
Number of subjects: 150
Study 19966092 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI SDS reduction >or=0.5
Number of subjects: 88
Study 19966092 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI SDS reduction >or=0.25
Number of subjects: 88
Study 17991690 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention for school-age children with type 1 diabetes
Number of subjects: 0
Study 17991690 — intervention group
Group type: COMPARATOR
Intervention: Maternal depressive symptoms
Number of subjects: 0
Study 15665739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus maintenance therapy after cyclosporine withdrawal
Number of subjects: 4
Study 15665739 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 4
Study 15665739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 4
Study 12164253 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraocular light (11,000 lux)
Number of subjects: 13
Study 12164253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10604410 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain PA-modified voice prostheses
Number of subjects: 18
Study 10604410 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain PA-modified voice prostheses
Number of subjects: 18
Study 10604410 — intervention group
Group type: COMPARATOR
Intervention: Control (original silicone rubber surfaces)
Number of subjects: 18
Study 7861018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine at 0.1 mg/kg/day
Number of subjects: 152
Study 7861018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine at 0.5 mg/kg/day
Number of subjects: 152
Study 7861018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine at 2.0 mg/kg/day
Number of subjects: 152
Study 1953510 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dose induction protocol
Number of subjects: 172
Study 1953510 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment by resident medical staff
Number of subjects: 172
Study 7372069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate therapy
Number of subjects: 59
Study 7372069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31410473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 438
Study 31410473 — intervention group
Group type: COMPARATOR
Intervention: GP-led care
Number of subjects: 438
Study 30081106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity decompression surgery
Number of subjects: 22
Study 30081106 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 22
Study 28193797 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD-VOO
Number of subjects: 296
Study 28193797 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD-Nuts
Number of subjects: 296
Study 28193797 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 296
Study 26223540 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing
Number of subjects: 300
Study 22336250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 6g/day
Number of subjects: 50
Study 22336250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21771118 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (n=342)
Number of subjects: 1018
Study 21771118 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of exclusive breastfeeding (≥4 vs. <4 months)
Number of subjects: 1018
Study 21771118 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=346)
Number of subjects: 1018
Study 19947445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (various classes including diuretics, calcium antagonists, ACE inhibitors, and angiotensin II receptor antagonists)
Number of subjects: 0
Study 19947445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17172556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (motor imagery and physical practice)
Number of subjects: 23
Study 17172556 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone (control group)
Number of subjects: 23
Study 16382598 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL (Kerr)
Number of subjects: 12
Study 16382598 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Classic (Vivadent)
Number of subjects: 12
Study 16382598 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion
Number of subjects: 12
Study 16382598 — intervention group
Group type: COMPARATOR
Intervention: Polishing
Number of subjects: 12
Study 12114906 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal phenobarbital exposure
Number of subjects: 436
Study 12114906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 12114906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage
Number of subjects: 436
Study 12114906 — intervention group
Group type: EXPERIMENTAL
Intervention: No intracranial hemorrhage
Number of subjects: 436
Study 9799205 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment elevation
Number of subjects: 12142
Study 9799205 — intervention group
Group type: COMPARATOR
Intervention: Non-ST-segment elevation
Number of subjects: 12142
Study 9799205 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation myocardial infarction
Number of subjects: 12142
Study 9799205 — intervention group
Group type: COMPARATOR
Intervention: Unstable angina
Number of subjects: 12142
Study 7696942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Sandoglobulin, Sandoz Pharmaceuticals) at a dose of 700 mg/kg for infants weighing 501-1000 g and 900 mg/kg for those weighing 1001-1500 g, repeated every 14 days until 1800 g or discharge/death
Number of subjects: 2416
Study 7696942 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions during phase I (n = 623), no infusion during phase II (n = 589)
Number of subjects: 2416